Back to search

Article

Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections

2024-12-01

Abstract excerpt

To compare the efficacy and safety of ceftazidime-avibactam (CAZ/AVI) and meropenem-vaborbactam (MER/VAB) in treating carbapenem-resistant Enterobacterales (CRE) infections. CRE infections pose significant clinical challenges due to limited treatment options. CAZ/AVI and MER/VAB are recommended therapies, yet robust data comparing these treatments are lacking. Multicentric retrospective cohort study on patients tr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
587cd9b9-1975-5726-83b2-6af9a80dbfee
DOI
10.1016/j.jgar.2024.10.011
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infectionsDOI 10.1016/j.jgar.2024.10.011
Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021Semantic proximity
Antimicrobial Susceptibility of Enterobacterales causing Bloodstream Infection in United States Medical Centres: Comparison of Aztreonam-Avibactam with Beta-Lactams Active against Carbapenem-Resistant EnterobacteralesSemantic proximity
Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?Semantic proximity
Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative BacteriaSemantic proximity
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020Semantic proximity
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.Semantic proximity
In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing EnterobacteralesSemantic proximity
Susceptibility of Ceftazidime-avibactam in bloodstream infections caused by multidrug-resistant Enterobacterales and Pseudomonas aeruginosaSemantic proximity
Ceftazidime-avibactam resistance determination in carbapenem-resistant Klebsiella pneumoniae infections before its use in practiceSemantic proximity
Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes.Semantic proximity
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing EnterobacteralesSemantic proximity
Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistanceSemantic proximity
Select a neighboring publication to make it the new centre.